17 December 2021

IQ-AI LIMITED

("IQ-AI" or the "Company")

IQ-AI Prepares for Phase I Clinical Trial Launch

IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI),

IQ-AI has been working with the clinical team at the Medical College of Wisconsin (MCW) to qualify a new supplier for encapsulating the drug candidate. The Company is pleased to announce that a supplier has been contracted and the production of the capsules is now underway. IQ-AI anticipates the trial will commence in February 2022.

While the qualification of a new supplier imposed a delay to the start of the trial, a robust source of supply is now ready to provide an efficient and continuous distribution of capsules to enrolled patients for this Phase I as well as subsequent trials.

"We appreciate everyone's efforts to secure an alternative encapsulation supplier for oral GaM and now await the start of this clinical trial," said Trevor Brown, CEO of IQ-AI.

The Directors of the Company accept responsibility for the contents of this announcement.

- ENDS-

For further information, please contact:

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of Imaging Biometrics, LLC (IB), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.